



A35478 066123.0125

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Tyagi et al.
Application No.: 10/687,402 Examiner: Fernandez, Susan
Filed: October 16, 2003 Art Unit: 1651
For: A SCREENING METHOD FOR DEVELOPING DRUGS AGAINST
PATHOGENIC MICROBES HAVING TWO-COMPONENT SYSTEM

INFORMATION DISCLOSURE STATEMENT

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Box 1450, Alexandria, VA 22313-1450.

December 6, 2004

Rochelle K. Seide

Attorney Name

Rochelle K. Seide

Signature

32,300

PTO Registration No

December 6, 2004

Date of Signature

Commissioner for Patents
Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§1.97 and 1.98, applicants respectfully request that the documents listed below and on the accompanying PTO 1449 be considered by the Examiner and made of record in the above-referenced application. Copies of the documents listed are enclosed.

1. Anderson D.H., Harth G., Horwitz M.A. and Eisenberg D. (2001) An interfacial mechanism and a class of inhibitors inferred from two crystal structures of the *Mycobacterium tuberculosis* 30 kDa major secretory protein (Antigen 85B), a mycolyl transferase. J. Mol. Biol. 307, 671 -681.

2. Armitige, L.Y., Jagannath, C., Wanger, A.R. and Norris, S.J. (2000) Disruption of gene encoding antigen 85A and 85B of *Mycobacterium tuberculosis* H37Rv: Effect on growth in culture and in macrophages. *Infect. Immun.* 68, 767 – 78.
3. Baikalov, I., Schroder, I., Kaczor – Grzeskowiak, M., Grzeskowiak, K., Gunsalus, R.P. and Dickerson, R.E. (1996) Structure of the *Escherichia coli* response regulator NarL. *Biochemistry* 35, 11053 - 11061.
4. Baltch, A.L., Smith, R.P., Ritz, W.J. and Bopp, L.H. (1998) Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and Ampicillin used singly and in combination against vancomycin – resistant *Enterococcus faecium*. *Antimicrob. Agents Chemother.* 42, 2564- 2568.
5. Barrett, J.F. and Hoch, J.A. (1998) Two-component signal transduction as a target for microbial anti – infective therapy. *Antimicrob. Agents Chemother.* 42, 1529-1536.
6. Barry, C.E. III, Slayden, R.A., Simpson, A.E. and Lee, R.E. (2000) Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs. *Biochem. Pharmacol.* 59, 221- 231.
7. Boon, C., Li, R., Qi, R. and Dick, T. (2001) Proteins of *Mycobacterium bovis* BCG induced in Wayne dormancy model. *J. Bacteriol.* 182, 2672 – 2676.
8. Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein – dye binding. *Anal. Biochem.* 72, 248 – 254.
9. Chen, P., Ruiz, R.E., Li, Q., Silver, R.F. and Bishai, W.R. (2000) Construction and characterization of *M. tuberculosis* mutant lacking the alternate sigma factor, *sigF*. *Infect. Immun.* 68, 5575 – 5580.
10. Cole, S.T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S.V., Eiglmeier, K., Gas, S., Barry, C.E. III, Tekaiia, F., Badcock, K., Bashyam, D., Brown, D., Chillingworth, T., Connor, R., Davies, R., Devlin, K., Feltwell, T., Gentles, S., Hamlin, N., Holroyd, S., Hornsby, T., Jagels, K., Krough, A., McLean, J., Moule, S., Murphy, L., Oliver, K., Osborne, J., Quail, M.A., Rajandream, M.A., Rogers, J., Rutter, S., Seeger, K., Skelton, J., Squares, R., Squares, S., Sulston, J.E., Taylor, K., Whirehead, S. and Barrell, B.G. (1998) Deciphering the biology of *Mycobacterium tuberculosis* from the complete genome sequence. *Nature* 393, 537 – 544.
11. Collins D.M., Kawakami R.P., de Lisle G.W., Pascopella L., Bloom B.R. and Jacobs W.R. Jr. (1995) Mutation of the principal sigma factor causes loss of virulence in a strain of the *Mycobacterium tuberculosis* complex. *Proc. Natl. Acad. Sci. USA* 92, 8036 - 8040.

12. Cooper J.B., McIntyre K., Badasso M.O., Wood S.P., Zhang Y., Garbe T.R. and Young, D. (1995) X-ray structure analysis of the iron-dependent superoxide dismutase from *Mycobacterium tuberculosis* at 2.0 Angstroms resolution reveals novel dimer-dimer interactions. *J. Mol. Biol.* 246, 531 – 544.
13. Cox J.S., Chen B., McNeil M. and Jacobs W.R. Jr. (1999) Complex lipid determines tissue-specific replication of *Mycobacterium tuberculosis* in mice, *Nature* 402, 79 - 83.
14. Dasgupta, N., Kapur, V., Singh, K.K., Das, T.K., Sachdeva, S., Jyothisri, K. and Tyagi, J.S. (2000) Characterization of a two-component system, *devR-devS*, of *Mycobacterium tuberculosis*. *Tuber. Lung Dis.* 80, 141 – 159.
15. DeMaio J., Zhang Y., Ko C., Young D.B. and Bishai W.R. (1996) A stationary-phase stress-response sigma factor from *Mycobacterium tuberculosis*. *Proc. Natl. Acad. Sci. (USA)* 93, 2790-2794.
16. Denis, A., Agouridas, C., Auger, J-M., Benedetti, Y., Bonnefoy, A., Bretin, F., Chantot, J.F., Dussarat, A., Fromentin, C., D'Ambrieres, S.G., Lachaud, S., Laurin, P., Le Martret, O., Loyau, V., Tessot, N., Pejac, J.M. and Perron S. (1999) Synthesis and antibacterial activity of HMR 3647, a new ketolide highly potent against erythromycin – resistant and susceptible pathogens. *Bioorg. Med. Chem. Lett.* 9, 3075 – 3080.
17. Deschenes, R.J., Lin, H., Ault, A.D. and Fassler, J.S. (1999) Antifungal properties and target evaluation of three putative bacterial histidine kinase inhibitors. *Antimicrob. Agents Chemother.* 43, 1700 – 1703.
18. Domagala, J.M., Alessi, D., Cummings, M., et al. (1998) Bacterial two-component signalling as a therapeutic target in drug design: Inhibition of NRII by diphenolic methanes (bisphenols). *Adv. Exp. Med. Biol.* 456, 269 – 286.
19. Doukhan, L., Predich, M., Nair, G., Dussurget, O., Mandic-Mulec, I., Cole, S.T., Smith, D.R. and Smith, I. (1995) Genomic organization of the mycobacterial sigma gene cluster. *Gene* 165, 67 - 70.
20. Dziejman, M. and Mekalanos, J.J. (1995) two-component signal transduction and its role in the expression of bacterial virulence factors in Hock, J.A. and Silhavy, T.J. Eds. Two component signal transduction. Washington , DC. American Society for Microbiology. Pp. 305-317.
21. El-Masry, A.H., Fahony, H.H. and Abdelwahed, S.H.A. (2000) Synthesis and anti microbial activity of some new benzimidazole derivatives. *Molecules* 5, 1429 – 1438.
22. Frechette, R.F., Beach, M.J., Bernstein, J. et al. (1997) Novel benzoxazine derivatives with inhibitory activity against bacterial two-component signal transduction systems. Abstract No. 152, Book of Abstracts, 214th ACS National Meeting, Las Vegas, NV, USA.

23. Glickman, M.S., Cox, J.S. and Jacobs, W.R. Jr. (2000) A novel mycolic acid cyclopropane synthetase is required for coding, persistence and virulence of *Mycobacterium tuberculosis*. *Mol. Cell* 5, 717 – 727.
24. Grange, J.M. (1992) The mystery of the mycobacterial ‘persistor’. *Tuber. Lung Dis.* 73, 249 – 251.
25. Haydel, S.E., Dunlap, N.E. and Benjamin, W.H. Jr. (1999) *In vitro* evidence of two-component system phosphorylation between the *Mycobacterium tuberculosis* TrcR/ TrcS proteins. *Micro. Patho.* 26 195-206.
26. Himpens, S., Locht, C. and Supply, P. (2000) Molecular characterization of the mycobacterial SenX3 – RegX3 two-component system: evidence for autoregulation. *Microbiol.* 146, 3091 – 3098.
27. Jackson, M., Crick, D.C. and Brennan, P.J. (2000) Phosphatidylinositol is an essential phospholipid of mycobacteria. *J. Biol. Chem.* 275, 30092 - 30099.
28. King, A.K. and Tyagi, J.S. (1993) Identification and cloning of genes differentially expressed in the virulent strain of *Mycobacterium tuberculosis*. *Gene* 131, 113 – 117.
29. Klimesova, V., Koc, J., Pour, M., Stachel, J., Waisser, K. and Kaustova, J. (2002a) Synthesis and preliminary evaluation of benzimidazole derivatives as antimicrobial agents. *Eur. J. Med. Chem.* 37, 409 – 418.
30. Klimesova, V., Koc, J., Waisser, K. and Kaustova, J. (2002b) New benzimidazole derivatives as antimycobacterial agents. *Il Farmaco*, 57, 259 – 265.
31. Kramer, MJ and Grunberg, E. (1973) Effect of ethidium bromide against transplantable tumors in mice and rats. *Chemotherapy*, 19, 254 - 258.
32. Phetsuksiri, B., Baulard, A.R., Cooper, A.M., Minnikin, D.E., Douglas, J.D., Besra, G.S. and Brennan, P.J. (1999) Antimycobacterial activities of isoxyl and new derivatives through the inhibition of mycolic acid synthesis. *Antimicrob. Chemother.* 43, 1042-1051.
33. Li, Z., Kelley, C., Collins, F., Rouse, D. and Morris, S. (1998) Expression of katG in *Mycobacterium tuberculosis* is associated with its growth and persistence in mice and guinea pigs. *J. Infect. Dis.* 177, 1030 – 1035.
34. Macielag, M.J. and Goldschmidt, R. (2000) Inhibitors of bacterial two-component signalling system. *Exp. Opin. Invest. Drugs* 9, 2351 – 2369.
35. Manganelli, R., Voskuil, M.I., Schoolnik, G.K. and Smith, I. (2001) The *Mycobacterium tuberculosis* ECF sigma factor sigmaE: role in global gene expression and survival in macrophages. *Mol. Microbiol.* 41, 423-437.

36. Matsushita, M. and Janda, K.D. (2002) Histidine kinases as targets for new antimicrobial agents. *Bioor. Med. Chem.* 10, 855 – 867.
37. Mayuri, Bagchi, G., Das, T.K. and Tyagi, J.S. (2002) Molecular analysis of the dormancy response in *Mycobacterium smegmatis*. Expression analysis of the genes encoding DevR – DevS two-component system, Rv3134c and chaperone – crystalline homologues. *FEMS Microbiol. Lett.* 211, 231 – 237.
38. McKinney, J.D., Bentrup, K.H., Munoz-Elias, E.J., Miczak, A., Chen, B., Chen, W.T., Swenson, D., Sacchettini, J.C., Jacobs, W.R. Jr. and Russell, D.G.. (2000) Persistence of *M. tuberculosis* in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. *Nature* 406, 735 – 738.
39. Mitchison, D.A. (1998) How drug resistance emerges as a result of poor compliance during short – chemotherapy for tuberculosis. *Int. J. Tuberc. Lung Dis.* 2, 10 – 15.
40. Mukamolova G.V., Kaprelyants A.S., Young D.I., Young M. and Kell D.B. (1998) A bacterial cytokine. *Proc. Natl. Acad. Sci. USA.* 95, 8916 - 8921.
41. Parkinson, J.S. and Kofoid, E.C. (1992) Communication modules in bacterial signalling proteins. *Ann. Rev. Genet.* 26, 71 – 112.
42. Parrish, N., Dick, J.D. and Bishai, W.R. (1998) Mechanisms of latency in *Mycobacterium tuberculosis*. *Trends Microbiol.* 6: 107 -112.
43. Perez, E., Samper, S., Bordas, Y., Guilhot, C., Gicquel, B. and Martin, C. (2001) An essential role for *phoP* in *Mycobacterium tuberculosis* virulence. *Mol. Micro.* 41, 179 – 87.
44. Pohl, E., Holmes, R.K. and Hol, W.G. (1999) Crystal structure of the iron-dependent regulator (IdeR) from *Mycobacterium tuberculosis* shows both metal binding sites fully occupied. *J. Mol. Biol.* 285, 1145 - 1156.
45. Raman, S., Song, T., Puyang, X., Bardarov, S., Jacobs, W.R. Jr. and Husson, R.N. (2001) The alternative sigma factor SigH regulates major components of oxidative and heat stress responses in *Mycobacterium tuberculosis*. *J. Bacteriol.* 183, 6119 - 6125.
46. Ronning, D.R., Klabunde, T., Besra, G.S., Vissa, V.D., Belisle, J.T. and Sacchettini, J.C. (2000) Crystal structure of the secreted form of antigen 85C reveals potential targets for mycobacterial drugs and vaccines. *Nat. Struct. Biol.* 7, 141 - 146.
47. Roychoudhary, S., Zielinski, N.A., Ninfa, A.J., Allen, N.E., Jungheim, L.N., Nicas, T.I. and Chakrabarty, A.M. (1993) Inhibitors of two-component signal transduction systems: Inhibition of alginate gene activation in *Pseudomonas aeruginosa*. *Proc. Natl. Acad. Sci. USA.* 90, 965 – 969.

48. Sherman, D.R., Voskuil, M., Schnappinger, D., Liao, R., Harrell, M.I. and Schoolnik, G.K. (2001) Regulation of the *Mycobacterium tuberculosis* hypoxia response gene encoding α -crystallin. *Proc. Natl. Acad. Sci. USA* 98, 7534 – 7539.
49. Stead, W.W. (1967) Pathogenesis of a first episode of chronic pulmonary tuberculosis in man: recrudescence of residuals of the primary infection or exogenous reinfection? *Am. Rev. Respir. Dis.* 95, 729 – 745.
50. Stead, W.W., Kerby, D.P., Schleuter, D.P. and Jordahl, C.W. (1968) The clinical spectrum of primary tuberculosis in adults. Confusion with reinfection in the pathogenesis of chronic tuberculosis. *Ann. Intern. Med.* 68, 731 – 745.
51. Stephenson, K., Yamaguchi, Y., Hoch, J.A. (2000) The mechanism of action of inhibitors of bacterial two-component signal transduction systems. *J. Biol. Chem.* 275, 38900 - 38904.
52. Stock, A.M., Robinson, V.L. and Goudreau, P.N. (2000) Two-component signal transduction. *Ann. Rev. Biochem.* 69, 183 – 215.
53. Stock, J.B., Surette, M.G., Levit, M. and Park, P. (1995) Two-component signal transduction systems: structure-function relationships and mechanisms of catalysis. In: Hock, J.A. and Silhavy, T.J. Eds. Two component signal transduction. Washington, DC. American Society for Microbiology. Pp. 25 – 51.
54. Stover, C.K., Warrenner, P., VanDevanter, D.R., Sherman, D.R., Arain, T.M., Langhorne, M.H., Anderson, S.W., Towell, J.A., Yuan, Y., McMurray, D.N., Kreiswirth, B.E., Barry, C.E. III and Baker, W.R. (2000) A small molecule nitroimidazofuran drug candidate for treatment of tuberculosis. *Nature* 405, 962 - 66.
55. Strauch, M.A., De Mendoza, D. and Hoch, J.A. (1992) cis – Unsaturated fatty acids specifically inhibit a signal – transducing protein kinase required for initiation of sporulation in *B. subtilis*. *Mol. Microbiol.* 6, 2909 – 2917.
56. Ulijasz, A.T. and Weisblum, B. (1999) Dissecting the VanRS signal transduction pathway with specific inhibitors. *J. Bacteriol.* 181, 627 – 631.
57. Upton, A., Johnson, N., Sandy, J. and Sim, E. (2001) Arylamine N-acetyltransferases - of mice, men and microorganisms. *Trends Pharmacol. Sci.* 22, 140 - 146.
58. Urbanski, M.J., Xiang, M.A., Foleno, B.D. et al. (1997) Novel cyclohexene derivatives with histidine protein kinase inhibitory activity - potential new antibacterial agents. Abstract No. 270, Book of Abstracts, 214th ACS National Meeting, Las Vegas, NV, USA.
59. Wallis, N.G. (1999) Bacterial two-component signal transduction systems as drug targets. *Curr. Opin. Anti-infect. Invest. Drugs.* 1, 428 – 434.

60. Weber, I., Fritz, C., Ruttkowski, S., Kreft, A. and Bange, F.-C. (2000) Anaerobic nitrate reductase (*narGHJI*) activity of *Mycobacterium bovis* BCG *in vitro* and its contribution to virulence in immunodeficient mice. *Mol. Microbiol.* 35, 1017 – 1025.
61. West, M.L. and Fairlie, D.P. (1995) Targeting HIV-1 protease: a test of drug-design methodologies. *Trends Pharmacol. Sci.* 16, 67 - 94.
62. WHO report on the Global Tuberculosis Epidemic (1998) WHO Geneva.
63. Wilson T.M., de Lisle, G.W. and Collins, D.M. (1995) Effect of *inhA* and *katG* on isoniazid resistance and virulence of *Mycobacterium bovis*. *Mol. Microbiol.* 15, 1009 - 1015.
64. Yuan, Y., Crane, D.C. , Simpson, R.M., Zhu, Y.Q., Hickey, M.J., Sherman, D.R. and Barry, C.E. III. (1998) The 16 kDa a - crystalline (Acr) protein of *Mycobacterium tuberculosis* is required for growth in macrophages. *Proc. Natl. Acad. Sci. USA* 95, 9578 – 9583.
65. Zahrt, T.C. and Deretic, V., (2000) An essential two-component signal transduction system in *Mycobacterium tuberculosis*. *J. Bacteriol.* 182, 3832 – 3838.
66. Zahrt, T.C and Deretic, V. (2001) *Mycobacterium tuberculosis* signal transduction system required for persistent infection. *Proc. Natl. Acad. Sci. (USA)* 98, 12706 - 11.
67. Zhang, Y. and Amzel, L.M. (2002) Tuberculosis drug targets. *Current Drug Targets* 3, 131 – 154.
68. Inouye, M., Heiyoung, P, Mitsuhide, I. (2000) Methods of identifying inhibitors of sensor kinases through rational drug design. Unites States Patent No. 6,162,627.
69. Tyagi, J.S. and Kapur, V. International PCT application “A process for identifying a novel target for the development of therapeutic modalities and drugs effective against tuberculosis”. Appl. No. PCT/IN02/00022.

Identification of the above-listed documents is not to be construed as an admission of the applicants or attorneys for applicants that such citations are available as “prior art” against the subject application.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the listed documents are material or constitute

“prior art.” If the Examiner applies the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute “prior art” under United States law, applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of the documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should the documents be applied against

PATENT

Pursuant to 37 C.F.R. § 1.97(b)(3), this Information Disclosure Statement is being filed, the applicants believe, before the mailing date of a first Office Action on the merits. Thus, there should be no fee required for this submission. However, if any fee is required, or if any overpayment has been made, the Commissioner is hereby authorized to charge any fees, or credit or any overpayments made, to Deposit Account 02-4377. A duplicate copy of this page is enclosed.

Respectfully submitted,

BAKER BOTTS L.L.P.

By: 

Rochelle K. Seide

Patent Office Reg. No. 32,300

Attorney for Applicants

30 Rockefeller Plaza

44th Floor

New York, NY 10112

(212) 408-2500


**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

Applicant
Tyagi et al.

Filing Date
October 16, 2003

Group
1651



U.S. PATENT DOCUMENTS

| *Exam. Init. | Document No. | Date | Name | Class | Subclass | Filing Date if Appropriate |
|--------------|---------------|------------|---------------|-------|----------|----------------------------|
| | 6 1 6 2 6 2 7 | 12/19/2000 | Inouye et al. | 435 | 194 | |
| | | | | | | |

FOREIGN PATENT DOCUMENT

| Document No. | Date | Country | Class | SubClass | Translation Yes No |
|-----------------|------------|---------|-------|----------|--------------------|
| 0 3 0 6 6 8 3 8 | 08/14/2003 | WIPO | | | |
| | | | | | |

OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)

| | |
|--|--|
| | Anderson D.H., Harth G., Horwitz M.A. and Eisenberg D. (2001) An interfacial mechanism and a class of inhibitors inferred from two crystal structures of the <i>Mycobacterium tuberculosis</i> 30 kDa major secretory protein (Antigen 85B) a mycolyl transferase. <i>J. Mol. Biol.</i> 307, 671 -681 |
| | Armitige, L.Y., Jagannath, C., Wanger, A.R. and Norris, S.J. (2000) Disruption of gene encoding antigen 85A and 85B of <i>Mycobacterium tuberculosis</i> H37Rv: Effect on growth in culture and in macrophages. <i>Infect. Immun.</i> 68, 76 - 78 |
| | Baikalov, I., Schroder, I., Kaczor - Grzeskowiak, M., Grzeskowiak, K., Gunsalus, R.P. and Dickerson, R.E. (1996) Structure of the <i>Escherichia coli</i> response regulator NarL. <i>Biochemistry</i> 35, 11053 - 11061 |
| | Baltch, A.L., Smith, R.P., Ritz, W.J. and Bopp, L.H. (1998) Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and Ampicillin used singly and in combination against vancomycin - resistant <i>Enterococcus faecium</i> . <i>Antimicrob. Agents Chemother.</i> 42, 2564- 2568 |
| | Barrett, J.F. and Hoch, J.A. (1998) Two-component signal transduction as a target for microbial anti - infective therapy. <i>Antimicrob. Agents Chemother.</i> 42, 1529-1536 |
| | Barry, C.E. III, Slayden, R.A., Simpson, A.E. and Lee, R.E. (2000) Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs. <i>Biochem. Pharmacol.</i> 59, 221- 231 |
| | Boon, C., Li, R., Qi, R. and Dick, T. (2001) Proteins of <i>Mycobacterium bovis</i> BCG induced in Wayne dormancy model. <i>J. Bacteriol.</i> 182, 2672 - 2676 |

NY02:505269.1

Examiner

Date Considered

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

Applicant
Tyagi et al.

Filing Date
October 16, 2003

Group
1651

Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein - dye binding. *Anal. Biochem.* 72, 248 - 254

Chen, P., Ruiz, R.E., Li, Q., Silver, R.F. and Bishai, W.R. (2000) Construction and characterization of *M. tuberculosis* mutant lacking the alternate sigma factor, *sigF*. *Infect. Immun.* 68, 5575 - 5580

Cole et al. (1998) Deciphering the biology of *Mycobacterium tuberculosis* from the complete genome sequence. *Nature* 393, 537 - 544

Collins D.M., Kawakami R.P., de Lisle G.W., Pascopella L., Bloom B.R. and Jacobs W.R. Jr. (1995) Mutation of the principal sigma factor causes loss of virulence in a strain of the *Mycobacterium tuberculosis* complex. *Proc. Natl Acad. Sci. USA* 92, 8036 - 8040

Cooper J.B., McIntyre K., Badasso M.O., Wood S.P., Zhang Y., Garbe T.R. and Young, D. (1995) X-ray structure analysis of the iron-dependent superoxide dismutase from *Mycobacterium tuberculosis* at 2.0 Angstroms resolution reveals novel dimer-dimer interactions. *J. Mol. Biol.* 246, 531 - 544

Cox J.S., Chen B., McNeil M. and Jacobs W.R. Jr. (1999) Complex lipid determines tissue-specific replication of *Mycobacterium tuberculosis* in mice, *Nature* 402, 79 - 83

Dasgupta, N., Kapur, V., Singh, K.K., Das, T.K., Sachdeva, S., Jyothisri, K. and Tyagi, J.S. (2000) Characterization of a two-component system, *devR-devS*, of *Mycobacterium tuberculosis*. *Tuber. Lung Dis.* 80, 141 - 159

DeMaio J., Zhang Y., Ko C., Young D.B. and Bishai W.R. (1996) A stationary-phase stress-response sigma factor from *Mycobacterium tuberculosis*. *Proc. Natl. Acad. Sci. (USA)* 93, 2790-2794

Denis et al. (1999) Synthesis and antibacterial activity of HMR 3647, a new ketolide highly potent against erythromycin - resistant and susceptible pathogens. *Bioorg. Med. Chem. Lett.* 9, 3075 - 3080

Deschenes, R.J., Lin, H., Ault, A.D. and Fassler, J.S. (1999) Antifungal properties and target evaluation of three putative bacterial histidine kinase inhibitors. *Antimicrob. Agents Chemother.* 43, 1700 - 1703

Domagala, J.M., Alessi, D., Cummings, M., et al. (1998) Bacterial two-component signalling as a therapeutic target in drug design: Inhibition of NRII by diphenolic methanes (bisphenols). *Adv. Exp. Med. Biol.* 456, 269 - 286

Doukhan, L., Predich, M., Nair, G., Dussurget, O., Mandic-Mulec, I., Cole, S.T., Smith, D.R. and Smith, I. (1995) Genomic organization of the mycobacterial sigma gene cluster. *Gene* 165, 67 - 70

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**
(Use several sheets if necessary)

Applicant
Tyagi et al.

Filing Date
October 16, 2003

Group
1651

- | | | |
|--|--|--|
| | | Dziejman, M. and Mekalanos, J.J. (1995) two-component signal transduction and its role in the expression of bacterial virulence factors in Hock, J.A. and Silhavy, T.J. Eds. Two component signal transduction. Washington, DC. American Society for Microbiology. Pp. 305-317 |
| | | El-Masry, A.H., Fahony, H.H. and Abdelwahed, S.H.A. (2000) Synthesis and anti microbial activity of some new benzimidazole derivatives. <i>Molecules</i> 5, 1429 – 1438 |
| | | Frechette, R.F., Beach, M.J., Bernstein, J. et al. (1997) Novel benzoxazine derivatives with inhibitory activity against bacterial two-component signal transduction systems. Abstract No. 152, Book of Abstracts, 214th ACS National Meeting, Las Vegas, NV, USA |
| | | Glickman, M.S., Cox, J.S. and Jacobs, W.R. Jr. (2000) A novel mycolic acid cyclopropane synthetase is required for coding, persistence and virulence of <i>Mycobacterium tuberculosis</i> . <i>Mol. Cell</i> 5, 717 – 727 |
| | | Grange, J.M. (1992) The mystery of the mycobacterial 'persistor'. <i>Tuber. Lung Dis.</i> 73, 249 – 251.. |
| | | Haydel, S.E., Dunlap, N.E. and Benjamin, W.H. Jr. (1999) <i>In vitro</i> evidence of two-component system phosphorylation between the <i>Mycobacterium tuberculosis</i> TrcR/ TrcS proteins <i>Micro. Patho.</i> 26 195-206 |
| | | Himpens, S., Loch, C. and Supply, P. (2000) Molecular characterization of the mycobacterial SenX3 – RegX3 two-component system: evidence for autoregulation. <i>Microbiol.</i> 146, 3091 – 3098 |
| | | Jackson, M., Crick, D.C. and Brennan, P.J. (2000) Phosphatidylinositol is an essential phospholipid of mycobacteria <i>J. Biol. Chem.</i> 275, 30092 - 30099 |
| | | Kinger, A.K. and Tyagi, J.S. (1993) Identification and cloning of genes differentially expressed in the virulent strain of <i>Mycobacterium tuberculosis</i> . <i>Gene</i> 131, 113 – 117 |
| | | Klimesova, V., Koc, J., Pour, M., Stachel, J., Waisser, K. and Kaustova, J. (2002a) Synthesis and preliminary evaluation of benzimidazole derivatives as antimicrobial agents. <i>Eur. J. Med. Chem.</i> 37, 409 – 418 |
| | | Klimesova, V., Koc, J., Waisser, K. and Kaustova, J. (2002b) New benzimidazole derivatives as antimycobacterial agents. <i>Il Farmaco</i> , 57, 259 – 265 |
| | | Kramer, MJ and Grunberg, E. (1973) Effect of ethidium bromide against transplantable tumors in mice and rats. <i>Chemotherapy</i> , 19, 254 - 258 |

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**
(Use several sheets if necessary)

Applicant
Tyagi et al.

Filing Date
October 16, 2003

Group
1651

| | | |
|--|--|---|
| | | Phetsuksiri, B., Baulard, A.R., Cooper, A.M., Minnikin, D.E., Douglas, J.D., Besra, G.S. and Brennan, P.J. (1999) Antimycobacterial activities of isoxyl and new derivatives through the inhibition of mycolic acid synthesis. <i>Antimicrob. Chemother.</i> 43, 1042-1051 |
| | | Li, Z., Kelley, C., Collins, F., Rouse, D. and Morris, S. (1998) Expression of katG in <i>Mycobacterium tuberculosis</i> is associated with its growth and persistence in mice and guinea pigs. <i>J. Infect. Dis.</i> 177, 1030 – 1035 |
| | | Macielag, M.J. and Goldschmidt, R. (2000) Inhibitors of bacterial two-component signalling system. <i>Exp. Opin. Invest. Drugs</i> 9, 2351 – 2369 |
| | | Manganelli, R., Voskuil, M.I., Schoolnik, G.K. and Smith, I. (2001) The <i>Mycobacterium tuberculosis</i> ECF sigma factor sigmaE: role in global gene expression and survival in macrophages. <i>Mol. Microbiol.</i> 41, 423-437 |
| | | Matsushita, M. and Janda, K.D. (2002) Histidine kinases as targets for new antimicrobial agents. <i>Bioor. Med. Chem.</i> 10, 855 – 867 |
| | | Mayuri, Bagchi, G., Das, T.K. and Tyagi, J.S. (2002) Molecular analysis of the dormancy response in <i>Mycobacterium smegmatis</i> . Expression analysis of the genes encoding DevR – DevS two-component system, Rv3134c and chaperone – crystalline homologues. <i>FEMS Microbiol. Lett.</i> 211, 231 – 237 |
| | | McKinney, J.D., Bentrup, K.H., Munoz-Elias, E.J., Miczak, A., Chen, B., Chen, W.T., Swenson, D., Sacchettini, J.C. Jacobs, W.R. Jr. and Russell, D.G.. (2000) Persistence of <i>M. tuberculosis</i> in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. <i>Nature</i> 406, 735 – 738 |
| | | Mitchison, D.A. (1998) How drug resistance emerges as a result of poor compliance during short – chemotherapy for tuberculosis. <i>Int. J. Tuberc. Lung Dis.</i> 2, 10 – 15 |
| | | Mukamolova G.V., Kaprelyants A.S., Young D.I., Young M. and Kell D.B. (1998) A bacterial cytokine. <i>Proc. Nat Acad. Sci. USA.</i> 95, 8916 - 8921 |
| | | Parkinson, J.S. and Kofoed, E.C. (1992) Communication modules in bacterial signalling proteins. <i>Ann. Rev. Genet.</i> 26, 71 – 112 |
| | | Parrish, N., Dick, J.D. and Bishai, W.R. (1998) Mechanisms of latency in <i>Mycobacterium tuberculosis</i> . <i>Trends Microbiol.</i> 6: 107 -112 |
| | | Perez, E., Samper, S., Bordas, Y., Guilhot, C., Gicquel, B. and Martin, C. (2001) An essential role for <i>phoP</i> in <i>Mycobacterium tuberculosis</i> virulence. <i>Mol. Micro.</i> 41, 179 – 87 |

NY02:505269.1

4

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

Applicant
Tyagi et al.

Filing Date
October 16, 2003

Group
1651

| | | |
|--|--|--|
| | | Pohl, E., Holmes, R.K. and Hol, W.G. (1999) Crystal structure of the iron-dependent regulator (IdeR) from <i>Mycobacterium tuberculosis</i> shows both metal binding sites fully occupied. <i>J. Mol. Biol.</i> 285, 1145 - 1156 |
| | | Raman, S., Song, T., Puyang, X., Bardarov, S., Jacobs, W.R. Jr. and Husson, R.N. (2001) The alternative sigma factor SigH regulates major components of oxidative and heat stress responses in <i>Mycobacterium tuberculosis</i> . <i>J. Bacteriol.</i> 183, 6119 - 6125 |
| | | Ronning, D.R., Klabunde, T., Besra, G.S., Vissa, V.D., Belisle, J.T. and Sacchettini, J.C. (2000) Crystal structure of the secreted form of antigen 85C reveals potential targets for mycobacterial drugs and vaccines. <i>Nat. Struct. Biol.</i> 7 141 - 146 |
| | | Roychoudhary, S., Zielinski, N.A., Ninfa, A.J., Allen, N.E., Jungheim, L.N., Nicas, T.I. and Chakrabarty, A.M. (1993) Inhibitors of two-component signal transduction systems: Inhibition of alginate gene activation in <i>Pseudomonas aeruginosa</i> . <i>Proc. Natl. Acad. Sci. USA</i> 90, 965 - 969 |
| | | Sherman, D.R., Voskuil, M., Schnappinger, D., Liao, R., Harrell, M.I. and Schoolnik, G.K. (2001) Regulation of the <i>Mycobacterium tuberculosis</i> hypoxia response gene encoding α -crystallin. <i>Proc. Natl. Acad. Sci. USA</i> 98, 7534 - 7539 |
| | | Stead, W.W. (1967) Pathogenesis of a first episode of chronic pulmonary tuberculosis in man: recrudescence of residuals of the primary infection or exogenous reinfection? <i>Am. Rev. Respir. Dis.</i> 95, 729 - 745 |
| | | Stead, W.W., Kerby, D.P., Schleuter, D.P. and Jordahl, C.W. (1968) The clinical spectrum of primary tuberculosis in adults. Confusion with reinfection in the pathogenesis of chronic tuberculosis. <i>Ann. Intern. Med.</i> 68, 731 - 745 |
| | | Stephenson, K., Yamaguchi, Y., Hoch, J.A. (2000) The mechanism of action of inhibitors of bacterial two-component signal transduction systems. <i>J. Biol. Chem.</i> 275, 38900 - 38904. |
| | | Stock, A.M., Robinson, V.L. and Goudreau, P.N. (2000) Two-component signal transduction. <i>Ann. Rev. Biochem</i> 69, 183 - 215 |
| | | Stock, J.B., Surette, M.G., Levit, M. and Park, P. (1995) Two-component signal transduction systems: structure-function relationships and mechanisms of catalysis. In: Hock, J.A. and Silhavy, T.J. Eds. Two component signal transduction. Washington, DC. American Society for Microbiology. Pp. 25 - 51 |
| | | Stover, C.K., Warren, P., VanDevanter, D.R., Sherman, D.R., Arain, T.M., Langhorne, M.H., Anderson, S.W., Towell, J.A., Yuan, Y., McMurray, D.N., Kreiswirth, B.E., Barry, C.E. III and Baker, W.R. (2000) A small molecule nitroimidazole drug candidate for treatment of tuberculosis. <i>Nature</i> 405, 962 - 66 |
| | | Strauch, M.A., De Mendoza, D. and Hoch, J.A. (1992) cis - Unsaturated fatty acids specifically inhibit a signal - transducing protein kinase required for initiation of sporulation in <i>B. subtilis</i> . <i>Mol. Microbiol.</i> 6, 2909 - 2917 |

NY02:505269.1

5

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**
(Use several sheets if necessary)

Applicant
Tyagi et al.

Filing Date
October 16, 2003

Group
1651

| | | |
|--|--|---|
| | | Ulijasz, A.T. and Weisblum, B. (1999) Dissecting the VanRS signal transduction pathway with specific inhibitors. <i>J Bacteriol.</i> 181, 627 – 631 |
| | | Upton, A., Johnson, N., Sandy, J. and Sim, E. (2001) Arylamine N-acetyltransferases - of mice, men and microorganisms. <i>Trends Pharmacol. Sci.</i> 22, 140 - 146 |
| | | Urbanski, M.J., Xiang, M.A., Foleno, B.D. et al. (1997) Novel cyclohexene derivatives with histidine protein kinase inhibitory activity - potential new antibacterial agents. Abstract No. 270, Book of Abstracts, 214th ACS National Meeting, Las Vegas, NV, USA |
| | | Wallis, N.G. (1999) Bacterial two-component signal transduction systems as drug targets. <i>Curr. Opin. Anti-infect. Invest. Drugs.</i> 1, 428 – 434 |
| | | Weber, I., Fritz, C., Rutkowski, S., Kreft, A. and Bange, F.-C. (2000) Anaerobic nitrate reductase (<i>narGHJI</i>) activity of <i>Mycobacterium bovis</i> BCG <i>in vitro</i> and its contribution to virulence in immunodeficient mice. <i>Mol. Microbiol.</i> 35 1017 – 1025 |
| | | West, M.L. and Fairlie, D.P. (1995) Targeting HIV-1 protease: a test of drug-design methodologies. <i>Trends Pharmacol. Sci.</i> 16, 67 - 94 |
| | | WHO report on the Global Tuberculosis Epidemic (1998) WHO Geneva |
| | | Wilson T.M., de Lisle, G.W. and Collins, D.M. (1995) Effect of <i>inhA</i> and <i>katG</i> on isoniazid resistance and virulence of <i>Mycobacterium bovis</i> . <i>Mol. Microbiol.</i> 15, 1009 - 1015 |
| | | Yuan, Y., Crane, D.C., Simpson, R.M., Zhu, Y.Q., Hickey, M.J., Sherman, D.R. and Barry, C.E. III. (1998) The 16 kDa a - crystalline (Acr) protein of <i>Mycobacterium tuberculosis</i> is required for growth in macrophages. <i>Proc. Natl. Acad. Sci. USA</i> 95, 9578 – 9583 |
| | | Zahrt, T.C. and Deretic, V., (2000) An essential two-component signal transduction system in <i>Mycobacterium tuberculosis</i> . <i>J. Bacteriol.</i> 182, 3832 – 3838 |
| | | Zahrt, T.C and Deretic, V. (2001) <i>Mycobacterium tuberculosis</i> signal transduction system required for persistent infection. <i>Proc. Natl. Acad. Sci. (USA)</i> 98, 12706 - 11 |
| | | Zhang, Y. and Amzel, L.M. (2002) Tuberculosis drug targets. <i>Current Drug Targets</i> 3, 131 – 154 |

NY02:505269.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.